Format

Send to

Choose Destination
Recenti Prog Med. 2015 Dec;106(12):629-33. doi: 10.1701/2094.22654.

[Regorafenib in patients with metastatic colorectal cancer: a review and an update].

[Article in Italian]

Abstract

Standard chemotherapy in patients with metastatic colorectal cancer is based on a combination of fluoropyrimidines, irinotecan and oxaliplatin. Regorafenib, an oral multikynase inhibitor blocking multiple disease progression-involved pathways, is a new therapeutic option in patients who already received standard therapy. In a phase III randomized, placebo-controlled study regorafenib, as compared to best supportive care, showed a statistically significant improvement in overall survival, irrespective of KRAS mutation status. Safety profile of regorafenib is acceptable, with few severe grade adverse events which can be adequately managed within few weeks after treatment beginning. Regorafenib is a new treatment standard in patients who already received chemotherapy for metastatic colorectal cancer.

PMID:
26780072
DOI:
10.1701/2094.22654
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Il Pensiero Scientifico Editore
Loading ...
Support Center